Close Menu

Vertex

NPR reports that the first person in the US to undergo a CRISPR-based treatment for sickle-cell disease continues to do well nearly a year after treatment.

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

Treatment So Far

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Doctors in the US have used CRISPR gene editing to try to treat a woman with sickle cell disease as part of a clinical trial, according to Popular Science.

A CRISPR Go

US companies have begun recruiting for a CRISPR-based gene-editing trial to treat β-thalassemia, Stat News reports.

Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.

In Science this week: pair of genomics studies on ancient animals, and more.

The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.

NEW YORK (GenomeWeb) — Vertex Pharmaceuticals this week released data from two Phase III studies of a combination of its cystic fibrosis drugs lumacaftor and Kalydeco (ivacaftor), showing that the studies have met their primary endpoints of statistically significant improvement in lung function a

Pages

Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.

Researchers report on a concerning strain of the H1N1 swine flu virus found among pigs in China, Agence France Presse reports.

The Associated Press reports that US officials are considering allowing pooled COVID-19 testing.

In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.